# Hubert Birner

> Hubert Birner is a Series A investor at TVM Capital (Munich) backing Medical and Health Care. See 10 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [TVM Capital](https://shizune.co/investors/profile/tvm-capital)
- Location: Munich, Germany
- Total investments: 10
- Last investment: Aug 2024
- Lead investor: 40%
- Last updated: Aug 2026
- LinkedIn: http://www.linkedin.com/pub/hubert-birner/3/b8b/563

Hubert Birner is a Series A investor at TVM Capital in Munich focused on Medical and Health Care. Hubert Birner is the Chairman of the board of directors of leon nanodrugs. Hubert Birner attended the Harvard Business School.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Medical | 3 | 30% |
| Health Care | 3 | 30% |
| Pharmaceutical | 3 | 30% |
| Biotechnology | 2 | 20% |
| SaaS | 1 | 10% |

7 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 2 | 20% |
| Series B | 2 | 20% |
| Series C | 2 | 20% |
| Series D | 2 | 20% |
| Funding Round | 1 | 10% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Germany | 2 | 20% |
| United States | 1 | 10% |
| The Netherlands | 1 | 10% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| leon nanodrugs | leon nanodrugs a specialised product development company dedicated to developing a pipeline of enhanced versions of existing drug products, and providing services to enable pre-clinical and clinical stage formulations for their clients NCEs or branded established drugs.leon-nanodrugs offers access to the next generation of nano-formulated drugswith meaningful differentiation and added patient benefits.They specialize in improving the bioavailability of poorly water soluble drugs by using leon’s proprietary MJR® Technology platform to create either polymeric or crystalline nanoparticles. |  | Series D | Aug 06, 2024 |  |
| Smart Reporting | Smart Reporting offers a digital health solution for structured medical reporting. Smart Reporting offers an intelligent software for physicians which improves quality and efficiency. The first platform was launched in radiology and supports radiologists in generating high-quality medical reports by applying guideline-compliant criteria in theirreports. | $24.5M | Series C | Apr 22, 2024 |  |
| leon nanodrugs | leon nanodrugs a specialised product development company dedicated to developing a pipeline of enhanced versions of existing drug products, and providing services to enable pre-clinical and clinical stage formulations for their clients NCEs or branded established drugs.leon-nanodrugs offers access to the next generation of nano-formulated drugswith meaningful differentiation and added patient benefits.They specialize in improving the bioavailability of poorly water soluble drugs by using leon’s proprietary MJR® Technology platform to create either polymeric or crystalline nanoparticles. |  | Series B | Apr 16, 2020 |  |
| leon nanodrugs | leon nanodrugs a specialised product development company dedicated to developing a pipeline of enhanced versions of existing drug products, and providing services to enable pre-clinical and clinical stage formulations for their clients NCEs or branded established drugs.leon-nanodrugs offers access to the next generation of nano-formulated drugswith meaningful differentiation and added patient benefits.They specialize in improving the bioavailability of poorly water soluble drugs by using leon’s proprietary MJR® Technology platform to create either polymeric or crystalline nanoparticles. |  | Series A | Jul 27, 2015 |  |
| Proteon Therapeutics | Proteon Therapeutics, Inc is a biopharmaceutical company developing pharmaceuticals to address the medical needs of patients with renal and vascular diseases.The company leverages a unique understanding of tissue remodeling to develop a pipeline of proprietary therapeutics.Proteon Therapeutics’ first drug candidate (PRT-201) is indevelopment for the improvement of blood flow following vascular surgery procedures. The company’s initial clinical focus is vascular access for hemodialysis and peripheral arterial disease (PAD). | $45M | Series D | May 16, 2014 |  |
| Proteon Therapeutics | Proteon Therapeutics, Inc is a biopharmaceutical company developing pharmaceuticals to address the medical needs of patients with renal and vascular diseases.The company leverages a unique understanding of tissue remodeling to develop a pipeline of proprietary therapeutics.Proteon Therapeutics’ first drug candidate (PRT-201) is indevelopment for the improvement of blood flow following vascular surgery procedures. The company’s initial clinical focus is vascular access for hemodialysis and peripheral arterial disease (PAD). | $15.2M | Series C | Aug 12, 2011 |  |
| Proteon Therapeutics | Proteon Therapeutics, Inc is a biopharmaceutical company developing pharmaceuticals to address the medical needs of patients with renal and vascular diseases.The company leverages a unique understanding of tissue remodeling to develop a pipeline of proprietary therapeutics.Proteon Therapeutics’ first drug candidate (PRT-201) is indevelopment for the improvement of blood flow following vascular surgery procedures. The company’s initial clinical focus is vascular access for hemodialysis and peripheral arterial disease (PAD). | $50M | Series B | May 28, 2009 |  |
| SpePharm | SpePharm is a European specialty pharmaceutical company dedicated to acquiring, registering and marketing high medical value medicines throughout Europe, essentially for the hospital market. The SpePharm management team has a wealth of global experience within the pharmaceutical industry. In particular, the team has a well-established and in-depthknowledge of the European regulatory system, the hospital market, and niche and orphan products, with novel approaches and proven successes. | $28.5M |  | Aug 21, 2008 |  |
| Proteon Therapeutics | Proteon Therapeutics, Inc is a biopharmaceutical company developing pharmaceuticals to address the medical needs of patients with renal and vascular diseases.The company leverages a unique understanding of tissue remodeling to develop a pipeline of proprietary therapeutics.Proteon Therapeutics’ first drug candidate (PRT-201) is indevelopment for the improvement of blood flow following vascular surgery procedures. The company’s initial clinical focus is vascular access for hemodialysis and peripheral arterial disease (PAD). | $12M | Series A | Sep 06, 2007 |  |
| Proteon Therapeutics | Proteon Therapeutics, Inc is a biopharmaceutical company developing pharmaceuticals to address the medical needs of patients with renal and vascular diseases.The company leverages a unique understanding of tissue remodeling to develop a pipeline of proprietary therapeutics.Proteon Therapeutics’ first drug candidate (PRT-201) is indevelopment for the improvement of blood flow following vascular surgery procedures. The company’s initial clinical focus is vascular access for hemodialysis and peripheral arterial disease (PAD). | $19M | Series A | Mar 30, 2006 |  |

10 of 10 investments shown.

## Co-investors
- [Intersouth Partners](https://shizune.co/investors/profile/intersouth-partners) — VC Fund, 5 deals together
- [Prism Venture Management](https://shizune.co/investors/profile/prism-venture-management) — VC Fund, 5 deals together
- [Skyline Ventures](https://shizune.co/investors/profile/skyline-ventures) — VC Fund, 5 deals together
- [Signet Healthcare Partners](https://shizune.co/investors/profile/signet-healthcare-partners) — VC Fund, 3 deals together
- [Albany Capital](https://shizune.co/investors/profile/albany-capital) — VC Fund, 2 deals together
- [CD-Venture](https://shizune.co/investors/profile/cd-venture) — VC Fund, 2 deals together

## About TVM Capital

VC Fund · Munich, Germany

TVM Capital is a global venture and growth capital firm that aims to finance select biopharmaceutical and medical device companies. TVM Capital was founded in 1983 and is based Munich, Bavaria.

5 contacts available at TVM Capital.

| Name | Title | Profile |
| --- | --- | --- |
| Hubert Birner | General Partner | https://shizune.co/investors/profile/hubert-birner |
| Luc Marengere | Managing Partner | https://shizune.co/investors/profile/luc-marengere |
| Christoph Schröder | General Partner | https://shizune.co/investors/profile/christoph-schrder |
| Friedrich Bornikoel | Managing Director | https://shizune.co/investors/profile/friedrich-bornikoel |
| Marc Riviere | General Partner | https://shizune.co/investors/profile/marc-rivi%C3%A8re |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Hubert Birner invest in?

Hubert Birner invests primarily in Medical, Health Care and Pharmaceutical startups, most often at Series A and Series B stage. Most of the 10 investments tracked by Shizune back companies in Germany. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Hubert Birner last invest?

The most recent investment recorded for Hubert Birner closed in Aug 2024. Shizune tracks 10 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co